Therapeutic Drug Monitoring of Antimicrobials - 2nd Volume

Dear Colleagues,

Currently, several therapeutic drug monitoring (TDM)-based strategies have been suggested to optimize antibacterial and antifungal dosing in special patient populations. Nevertheless, a few obstacles still need to be addressed before TDM-based dosing strategies can be deployed widely in routine clinical practice.

Volume 1 of this Special Issue addressed suboptimal exposure to antibiotics and antifungals and knowledge on their pharmacokinetic/pharmacodynamic relationship in special patient populations. In these studies, recommendations and areas for further research have been identified. Additionally, for many antimicrobials, the link between exposure and clinical outcome remains to be confirmed. The topic of this Special Issue therefore remains of utmost relevance to the overarching topic of this journal. Consequently, we intend to keep this Special Issue open for submissions as a tool to communicate and interact between clinical researchers.

In the present volume 2 of this Special Issue, papers that further refine our understanding of antimicrobial TDM and its potential benefits in both adult and pediatric patients are welcomed. In particular, papers addressing the potential clinical benefit of antimicrobial TDM-based dose optimization and those addressing antiviral TDM-based dose optimization strategies are welcome, as these constitute major gaps in the current literature.

This Special Issue welcomes all types of submissions (original research papers, short communications, reviews, case reports and perspectives) related to antimicrobial TDM in special patient populations, including but not limited to critically ill patients, children, neonates, obese patients, hematological patients, and patients with cystic fibrosis.

Dr. Matthias Gijsen
Prof. Dr. Karel Allegaert
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.